

Olaf H Klungel

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5078967/olaf-h-klungel-publications-by-year.pdf>

Version: 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

117
papers

2,671
citations

23
h-index

49
g-index

127
ext. papers

3,406
ext. citations

4.5
avg, IF

4.86
L-index

#	Paper	IF	Citations
117	Impact of vomiting on P2Y12 platelet inhibition in patients with ST-elevation myocardial infarction: A prespecified subanalysis of the ON-TIME 3 trial. <i>American Heart Journal</i> , 2022 , 243, 39-42	4.9	
116	Characteristics of patients with lung cancer in clinical practice and their potential eligibility for clinical trials evaluating tyrosine kinase inhibitors or immune checkpoint inhibitors.. <i>Cancer Epidemiology</i> , 2022 , 78, 102149	2.8	
115	Mapping the risk of infections in patients with multiple sclerosis: A multi-database study in the United Kingdom Clinical Practice Research Datalink GOLD and Aurum.. <i>Multiple Sclerosis Journal</i> , 2022 , 13524585221094218	5	1
114	Incidence, hospitalization and mortality and their changes over time in people with a first ever diabetic foot ulcer. <i>Diabetic Medicine</i> , 2021 , e14725	3.5	2
113	Greedy caliper propensity score matching can yield variable estimates of the treatment-outcome association-A simulation study. <i>Pharmacoepidemiology and Drug Safety</i> , 2021 , 30, 934-951	2.6	4
112	Real-world outcomes versus clinical trial results of immunotherapy in stage IV non-small cell lung cancer (NSCLC) in the Netherlands. <i>Scientific Reports</i> , 2021 , 11, 6306	4.9	10
111	Response to: Kumar N, Ahmed M. Letter to the editor in response to Komen et al. 2021. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, e31	6.4	1
110	Impact of anticoagulant exposure misclassification on the bleeding risk of direct oral anticoagulants. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 3508-3517	3.8	1
109	A systematic review of how missing data are handled and reported in multi-database pharmacoepidemiologic studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2021 , 30, 819-826	2.6	1
108	Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies. <i>Clinical and Translational Science</i> , 2021 , 14, 1566-1577	4.9	0
107	Persistence and adherence to non-vitamin K antagonist oral anticoagulant treatment in patients with atrial fibrillation across five Western European countries. <i>Europace</i> , 2021 , 23, 1722-1730	3.9	2
106	Global covid-19 vaccine rollout and safety surveillance-how to keep pace. <i>BMJ, The</i> , 2021 , 373, n1416	5.9	5
105	Determinants of treatment modification before and after implementation of the updated 2015 NICE guideline on type 2 diabetes: A retrospective cohort study. <i>Diabetes Research and Clinical Practice</i> , 2021 , 176, 108828	7.4	
104	Comprehensive evaluation of post-approval regulatory actions during the drug lifecycle - a focus on benefits and risks. <i>Expert Opinion on Drug Safety</i> , 2021 , 20, 1433-1442	4.1	0
103	Long-term persistence and adherence with non-vitamin K oral anticoagulants in patients with atrial fibrillation and their associations with stroke risk. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, f72-f80	6.4	12
102	Comparing risk of major bleeding between users of different oral anticoagulants in patients with nonvalvular atrial fibrillation. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 988-1000	3.8	3
101	Prescribers compliance with summary of product characteristics of dabigatran, rivaroxaban and apixaban-A European comparative drug utilization study. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2021 , 128, 440-454	3.1	1

100	Systematic evaluation of the efficacy-effectiveness gap of systemic treatments in extensive disease small cell lung cancer. <i>Pharmacoepidemiology and Drug Safety</i> , 2021 , 30, 445-450	2.6	1
99	Association of preceding antithrombotic therapy in atrial fibrillation patients with ischaemic stroke, intracranial haemorrhage, or gastrointestinal bleed and mortality. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, 3-10	6.4	7
98	Estimation of manufacturing development costs of cell-based therapies: a feasibility study. <i>Cytotherapy</i> , 2021 , 23, 730-739	4.8	3
97	Effect of metabolic genetic variants on long-term disease comorbidity in patients with type 2 diabetes. <i>Scientific Reports</i> , 2021 , 11, 2794	4.9	
96	Use of Sodium-Glucose Co-Transporter-2-Inhibitors (SGLT2-Is) and Risk of Lower Limb Amputation. <i>Current Drug Safety</i> , 2021 , 16, 62-72	1.4	4
95	Major bleeding in users of direct oral anticoagulants in atrial fibrillation: A pooled analysis of results from multiple population-based cohort studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2021 , 30, 1339-1352	2.6	4
94	Thiazolidinediones and Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Nonalcoholic Fatty Liver Disease: A Cohort Study. <i>Hepatology</i> , 2021 , 74, 2467-2477	11.2	2
93	Drug exposure misclassification in pharmacoepidemiology: Sources and relative impact. <i>Pharmacoepidemiology and Drug Safety</i> , 2021 , 30, 1703-1715	2.6	0
92	Considerations for pharmacoepidemiological analyses in the SARS-CoV-2 pandemic. <i>Pharmacoepidemiology and Drug Safety</i> , 2020 , 29, 825-831	2.6	18
91	Quality of reporting of drug exposure in pharmacoepidemiological studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2020 , 29, 1141-1150	2.6	1
90	Application of Healthcare Big Data in CNS Drug Research: The Example of the Neurological and mental health Global Epidemiology Network (NeuroGEN). <i>CNS Drugs</i> , 2020 , 34, 897-913	6.7	5
89	A novel method for predicting the budget impact of innovative medicines: validation study for oncolytics. <i>European Journal of Health Economics</i> , 2020 , 21, 845-853	3.6	1
88	Development and Regulation of Gene and Cell-Based Therapies in Europe: A Quantification and Reflection. <i>Trends in Pharmacological Sciences</i> , 2020 , 41, 67-71	13.2	3
87	Increasing the information provided by probabilistic sensitivity analysis: The relative density plot. <i>Cost Effectiveness and Resource Allocation</i> , 2020 , 18, 54	2.4	0
86	The Role of Regulator-Imposed Post-Approval Studies in Health Technology Assessments for Conditionally Approved Drugs. <i>International Journal of Health Policy and Management</i> , 2020 ,	2.5	5
85	Concomitant Anticoagulant and Antidepressant Therapy in Atrial Fibrillation Patients and Risk of Stroke and Bleeding. <i>Clinical Pharmacology and Therapeutics</i> , 2020 , 107, 287-294	6.1	4
84	Affordability of oncology drugs: accuracy of budget impact estimations. <i>Journal of Market Access & Health Policy</i> , 2020 , 8, 1697558	3.7	1
83	Effect of *22 and Genetic Variants on Platelet Reactivity in Patients Treated with Clopidogrel and Lipid-Lowering Drugs Undergoing Elective Percutaneous Coronary Intervention. <i>Genes</i> , 2020 , 11,	4.2	1

82	What does cell therapy manufacturing cost? A framework and methodology to facilitate academic and other small-scale cell therapy manufacturing costings. <i>Cytotherapy</i> , 2020 , 22, 388-397	4.8	11
81	Assessment of the Regulatory Dialogue Between Pharmaceutical Companies and the European Medicines Agency on the Choice of Noninferiority Margins. <i>Clinical Therapeutics</i> , 2020 , 42, 1588-1594	3.5	0
80	Association of Factor V Leiden With Subsequent Atherothrombotic Events: A GENIUS-CHD Study of Individual Participant Data. <i>Circulation</i> , 2020 , 142, 546-555	16.7	5
79	Rivaroxaban was found to be noninferior to warfarin in routine clinical care: A retrospective noninferiority cohort replication study. <i>Pharmacoepidemiology and Drug Safety</i> , 2020 , 29, 1263-1272	2.6	1
78	Impact of opioids on P2Y12-receptor inhibition in patients with ST-elevation myocardial infarction who are pre-treated with crushed ticagrelor: Opioids and crushed Ticagrelor In Myocardial infarction Evaluation (ON-TIME 3) trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020 ,	6.4	13
77	A Review of Methodological Considerations for Economic Evaluations of Gene Therapies and Their Application in Literature. <i>Value in Health</i> , 2020 , 23, 1268-1280	3.3	6
76	Managing Uncertainties Due to Limited Evidence in Economic Evaluations of Novel Anti-Tuberculosis Regimens: A Systematic Review. <i>PharmacoEconomics - Open</i> , 2020 , 4, 223-233	2.1	1
75	Impact of the definition of osteoarthritis and of the timing of its onset on the association between type 2 diabetes mellitus and osteoarthritis: Clinical Practice Research Datalink. <i>Diabetes Research and Clinical Practice</i> , 2019 , 148, 240-248	7.4	2
74	Subsequent Event Risk in Individuals With Established Coronary Heart Disease. <i>Circulation Genomic and Precision Medicine</i> , 2019 , 12, e002470	5.2	13
73	Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events. <i>Circulation Genomic and Precision Medicine</i> , 2019 , 12, e002471	5.2	14
72	Cyclo-oxygenase selectivity and chemical groups of nonsteroidal anti-inflammatory drugs and the frequency of reporting hypersensitivity reactions: a case/noncase study in VigiBase. <i>Fundamental and Clinical Pharmacology</i> , 2019 , 33, 589-600	3.1	2
71	Conditional Financing of Drugs in the Netherlands: Past, Present, and Future-Results From Stakeholder Interviews. <i>Value in Health</i> , 2019 , 22, 399-407	3.3	6
70	Risk of myocardial infarction associated with non-steroidal anti-inflammatory drugs: Impact of additional confounding control for variables collected from self-reported data. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2019 , 44, 623-631	2.2	3
69	Accuracy of budget impact estimations and impact on patient access: a hepatitis C case study. <i>European Journal of Health Economics</i> , 2019 , 20, 857-867	3.6	4
68	Postauthorization Changes to Specific Obligations of Conditionally Authorized Medicines in the European Union: A Retrospective Cohort Study. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 105, 426-435	6.1	6
67	Non-steroidal anti-inflammatory drugs and the risk of out-of-hospital cardiac arrest: a case-control study. <i>Europace</i> , 2019 , 21, 99-105	3.9	1
66	Amiodarone use and the risk of acute pancreatitis: Influence of different exposure definitions. <i>Pharmacoepidemiology and Drug Safety</i> , 2019 , 28, 1563-1571	2.6	1
65	Risk of Nephrotic Syndrome for Non-Steroidal Anti-Inflammatory Drug Users. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019 , 14, 1355-1362	6.9	16

64	Incidence of direct oral anticoagulant use in patients with nonvalvular atrial fibrillation and characteristics of users in 6 European countries (2008-2015): A cross-national drug utilization study. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 2524-2539	3.8	29
63	The International Society for Pharmacoepidemiology's Comments on the Core Recommendations in the Summary of the Heads of Medicines Agencies (HMA) - EMA Joint Big Data Task Force. <i>Pharmacoepidemiology and Drug Safety</i> , 2019 , 28, 1640-1641	2.6	1
62	Distributed Networks of Databases Analyzed Using Common Protocols and/or Common Data Models 2019 , 617-638		5
61	How pharmacoepidemiology networks can manage distributed analyses to improve replicability and transparency and minimize bias. <i>Pharmacoepidemiology and Drug Safety</i> , 2019 , 29, 3	2.6	18
60	Risk of a first-ever acute myocardial infarction and all-cause mortality with sulphonylurea treatment: A population-based cohort study. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 1056-1060	6.7	6
59	Medications Recommended for Secondary Prevention After First Acute Coronary Syndrome: Effectiveness of Treatment Combinations in a Real-Life Setting. <i>Clinical Pharmacology and Therapeutics</i> , 2018 , 103, 1038-1046	6.1	5
58	Disparities in model-based cost-effectiveness analyses of tuberculosis diagnosis: A systematic review. <i>PLoS ONE</i> , 2018 , 13, e0193293	3.7	2
57	Using a single noninferiority margin or preserved fraction for an entire pharmacological class was found to be inappropriate. <i>Journal of Clinical Epidemiology</i> , 2018 , 104, 15-23	5.7	2
56	Pattern of risks of rheumatoid arthritis among patients using statins: A cohort study with the clinical practice research datalink. <i>PLoS ONE</i> , 2018 , 13, e0193297	3.7	9
55	Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies. <i>Pharmacoeconomics</i> , 2018 , 36, 359-368	4.4	43
54	Patients' Beliefs about medicine are associated with early thiopurine discontinuation in patients with inflammatory bowel diseases. <i>European Journal of Gastroenterology and Hepatology</i> , 2018 , 30, 167-173	2.2	8
53	The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). <i>BMJ, The</i> , 2018 , 363, k3532	5.9	110
52	Challenges in Advanced Therapy Medicinal Product Development: A Survey among Companies in Europe. <i>Molecular Therapy - Methods and Clinical Development</i> , 2018 , 11, 121-130	6.4	40
51	Social media as a tool for assessing patient perspectives on quality of life in metastatic melanoma: a feasibility study. <i>Health and Quality of Life Outcomes</i> , 2018 , 16, 222	3	4
50	Systematic evaluation of the efficacy-effectiveness gap of systemic treatments in metastatic nonsmall cell lung cancer. <i>European Respiratory Journal</i> , 2018 , 52,	13.6	18
49	Pharmacoepidemiological Approaches for Population-Based Hypothesis Testing. <i>Methods in Pharmacology and Toxicology</i> , 2018 , 201-216	1.1	
48	Exploring the role of low-frequency and rare exonic variants in alcohol and tobacco use. <i>Drug and Alcohol Dependence</i> , 2018 , 188, 94-101	4.9	7
47	Comparative effectiveness of recommended versus less intensive drug combinations in secondary prevention of acute coronary syndrome. <i>Pharmacoepidemiology and Drug Safety</i> , 2017 , 26, 285-293	2.6	14

46	Defining the noninferiority margin and analysing noninferiority: An overview. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 1636-1642	3.8	66
45	Gastrointestinal toxicity among patients taking selective COX-2 inhibitors or conventional NSAIDs, alone or combined with proton pump inhibitors: a case-control study. <i>Pharmacoepidemiology and Drug Safety</i> , 2017 , 26, 1141-1148	2.6	19
44	Methods of defining the non-inferiority margin in randomized, double-blind controlled trials: a systematic review. <i>Trials</i> , 2017 , 18, 107	2.8	32
43	Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0. <i>Value in Health</i> , 2017 , 20, 1009-1022	3.3	47
42	Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0. <i>Pharmacoepidemiology and Drug Safety</i> , 2017 , 26, 1018-1032	2.6	78
41	More Dose-dependent Side Effects with Mercaptopurine over Azathioprine in IBD Treatment Due to Relatively Higher Dosing. <i>Inflammatory Bowel Diseases</i> , 2017 , 23, 1873-1881	4.5	15
40	The impact of serum potassium-influencing antihypertensive drugs on the risk of out-of-hospital cardiac arrest: A case-control study. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 2541-2548	3.8	6
39	The impact of age and sex on the reporting of cough and angioedema with renin-angiotensin system inhibitors: a case/noncase study in VigiBase. <i>Fundamental and Clinical Pharmacology</i> , 2017 , 31, 676-684	3.1	17
38	Pattern of risks of systemic lupus erythematosus among statin users: a population-based cohort study. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1723-1730	2.4	9
37	Patterns of antiplatelet drug use after a first myocardial infarction during a 10-year period. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 632-641	3.8	7
36	Early Assessment of Thiopurine Metabolites Identifies Patients at Risk of Thiopurine-induced Leukopenia in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2017 , 11, 175-184	1.5	36
35	Best (but oft-forgotten) practices: propensity score methods in clinical nutrition research. <i>American Journal of Clinical Nutrition</i> , 2016 , 104, 247-58	7	23
34	Unmeasured confounding in pharmacoepidemiology. <i>Annals of Epidemiology</i> , 2016 , 26, 85-6	6.4	7
33	Case-only designs for studying the association of antidepressants and hip or femur fracture. <i>Pharmacoepidemiology and Drug Safety</i> , 2016 , 25 Suppl 1, 103-13	2.6	10
32	Methods to control for unmeasured confounding in pharmacoepidemiology: an overview. <i>International Journal of Clinical Pharmacy</i> , 2016 , 38, 714-23	2.3	24
31	Understanding inconsistency in the results from observational pharmacoepidemiological studies: the case of antidepressant use and risk of hip/femur fractures. <i>Pharmacoepidemiology and Drug Safety</i> , 2016 , 25 Suppl 1, 88-102	2.6	21
30	Instrumental variables analysis using multiple databases: an example of antidepressant use and risk of hip fracture. <i>Pharmacoepidemiology and Drug Safety</i> , 2016 , 25 Suppl 1, 122-31	2.6	5
29	Do case-only designs yield consistent results across design and different databases? A case study of hip fractures and benzodiazepines. <i>Pharmacoepidemiology and Drug Safety</i> , 2016 , 25 Suppl 1, 79-87	2.6	11

28	Exposure to benzodiazepines (anxiolytics, hypnotics and related drugs) in seven European electronic healthcare databases: a cross-national descriptive study from the PROTECT-EU Project. <i>Pharmacoepidemiology and Drug Safety</i> , 2016 , 25 Suppl 1, 56-65	2.6	73
27	Prevalence of antibiotic use: a comparison across various European health care data sources. <i>Pharmacoepidemiology and Drug Safety</i> , 2016 , 25 Suppl 1, 11-20	2.6	40
26	The risk of acute liver injury among users of antibiotic medications: a comparison of case-only studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2016 , 25 Suppl 1, 39-46	2.6	4
25	Evaluating different physician prescribing preference based instrumental variables in two primary care databases: a study of inhaled long-acting beta2-agonist use and the risk of myocardial infarction. <i>Pharmacoepidemiology and Drug Safety</i> , 2016 , 25 Suppl 1, 132-41	2.6	7
24	Risk of acute liver injury associated with use of antibiotics. Comparative cohort and nested case-control studies using two primary care databases in Europe. <i>Pharmacoepidemiology and Drug Safety</i> , 2016 , 25 Suppl 1, 29-38	2.6	14
23	Methodological comparison of marginal structural model, time-varying Cox regression, and propensity score methods: the example of antidepressant use and the risk of hip fracture. <i>Pharmacoepidemiology and Drug Safety</i> , 2016 , 25 Suppl 1, 114-21	2.6	16
22	Impact of varying outcomes and definitions of suicidality on the associations of antiepileptic drugs and suicidality: comparisons from UK Clinical Practice Research Datalink (CPRD) and Danish national registries (DNR). <i>Pharmacoepidemiology and Drug Safety</i> , 2016 , 25 Suppl 1, 142-55	2.6	10
21	The IMI PROTECT project: purpose, organizational structure, and procedures. <i>Pharmacoepidemiology and Drug Safety</i> , 2016 , 25 Suppl 1, 5-10	2.6	17
20	Multi-centre, multi-database studies with common protocols: lessons learnt from the IMI PROTECT project. <i>Pharmacoepidemiology and Drug Safety</i> , 2016 , 25 Suppl 1, 156-65	2.6	33
19	Left truncation results in substantial bias of the relation between time-dependent exposures and adverse events. <i>Annals of Epidemiology</i> , 2015 , 25, 590-6	6.4	13
18	Bayesian methods including nonrandomized study data increased the efficiency of postlaunch RCTs. <i>Journal of Clinical Epidemiology</i> , 2015 , 68, 387-96	5.7	3
17	Comparative Performance of ATRIA, CHADS2, and CHA2DS2-VASc Risk Scores Predicting Stroke in Patients With Atrial Fibrillation: Results From a National Primary Care Database. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 1851-9	15.1	116
16	HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. <i>Lancet, The</i> , 2015 , 385, 351-61	40	409
15	Risk patterns in drug safety study using relative times by accelerated failure time models when proportional hazards assumption is questionable: an illustrative case study of cancer risk of patients on glucose-lowering therapies. <i>Pharmaceutical Statistics</i> , 2015 , 14, 382-94	1	3
14	Reporting of covariate selection and balance assessment in propensity score analysis is suboptimal: a systematic review. <i>Journal of Clinical Epidemiology</i> , 2015 , 68, 112-21	5.7	176
13	Time trends of period prevalence rates of patients with inhaled long-acting beta-2-agonists-containing prescriptions: a European comparative database study. <i>PLoS ONE</i> , 2015 , 10, e0117628	3.7	9
12	Antiepileptic drug use in seven electronic health record databases in Europe: a methodologic comparison. <i>Epilepsia</i> , 2014 , 55, 666-673	6.4	30
11	Association between alcohol and cardiovascular disease: Mendelian randomisation analysis based on individual participant data. <i>BMJ, The</i> , 2014 , 349, g4164	5.9	406

10	Exploring interaction effects in small samples increases rates of false-positive and false-negative findings: results from a systematic review and simulation study. <i>Journal of Clinical Epidemiology</i> , 2014 , 67, 821-9	5.7	35
9	Justification of exclusion criteria was underreported in a review of cardiovascular trials. <i>Journal of Clinical Epidemiology</i> , 2014 , 67, 635-44	5.7	20
8	Utilisation and off-label prescriptions of respiratory drugs in children. <i>PLoS ONE</i> , 2014 , 9, e105110	3.7	6
7	Giant cell arteritis and polymyalgia rheumatica after reexposure to a statin: a case report. <i>Annals of Internal Medicine</i> , 2014 , 161, 614-5	8	9
6	Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study. <i>Journal of the American College of Cardiology</i> , 2013 , 62, 1966-1976	15.1	91
5	Statins accelerate the onset of collagen type II-induced arthritis in mice. <i>Arthritis Research and Therapy</i> , 2012 , 14, R90	5.7	18
4	Statin-associated polymyalgia rheumatica. An analysis using WHO global individual case safety database: a case/non-case approach. <i>PLoS ONE</i> , 2012 , 7, e41289	3.7	22
3	Association between statin use and lupus-like syndrome using spontaneous reports. <i>Seminars in Arthritis and Rheumatism</i> , 2011 , 41, 373-81	5.3	24
2	Increased bleeding risk with concurrent use of selective serotonin reuptake inhibitors and coumarins. <i>Archives of Internal Medicine</i> , 2008 , 168, 180-5		98
1	Sex differences in the medication choice for hypertension in general practice. A study with written case simulations. <i>International Journal of Clinical Pharmacy</i> , 2000 , 22, 140-6		4